Exhibit 10.24
Confidential Treatment Requested
Under 17 C.F.R. Sections 200.80(b)(4),
200.83 and 230.406
*** Indicates omitted material that is the subject of a confidential
treatment request filed separately with the Commission.
TARGET DISCOVERY COLLABORATION
AND LICENSE AGREEMENT
BETWEEN
GENE LOGIC INC.
AND
PROCTER & XXXXXX PHARMACEUTICALS, INC.
DATED AS OF MAY 27, 1997
Table Of Contents
Page
1. DEFINITIONS........................................................... 1
1.1 "Affiliate"...................................................... 1
1.2 "Agreement Term"................................................. 2
1.3 "Alliance Director".............................................. 2
1.4 "cDNA"........................................................... 2
1.5 "cDNA Sequence Analysis"......................................... 2
1.6 "Commercialization Field"........................................ 2
1.7 "Control"........................................................ 2
1.8 "Diagnostic Product"............................................. 2
1.9 "Drug Approval Application"...................................... 2
1.10 "Effective Date"................................................. 2
1.11 "FDA"............................................................ 2
1.12 "Field".......................................................... 2
1.13 "Further Research and Development"............................... 3
1.14 "Gene Product"................................................... 3
1.15 "Gene Target".................................................... 3
1.16 "Gene Logic Software"............................................ 3
1.17 "Gene Logic Technology".......................................... 3
1.18 "Heart Failure".................................................. 3
1.19 "IND"............................................................ 3
1.20 "Invention(s)"................................................... 3
1.21 "Major Market"................................................... 3
1.22 "NDA"............................................................ 3
1.23 "Net Sales"...................................................... 3
1.24 "Patent Right(s)"................................................ 4
1.25 "Product"........................................................ 4
1.26 "Protein Product"................................................ 4
1.27 "Regulatory Approval"............................................ 4
1.28 "Research Database".............................................. 5
1.29 "Research Management Committee" or "RMC"......................... 5
1.30 "Research Plan".................................................. 5
1.31 "Research Program"............................................... 5
1.32 "Research Term".................................................. 5
1.33 "Samples"........................................................ 5
1.34 "Scientific FTE"................................................. 5
1.35 "Stage I"........................................................ 5
TABLE OF CONTENTS
(CONTINUED)
Page
1.36 "Stage II"...................................................... 5
1.37 "Therapeutic Product"........................................... 5
1.38 "Third Party"................................................... 6
1.39 "Utility"....................................................... 6
2. Research Program..................................................... 6
2.1 Undertaking and Scope........................................... 6
2.2 Personnel and Resources......................................... 6
2.3 Establishment of Link to Research Database...................... 6
2.4 Term of the Research Program.................................... 7
2.5 Selection of Gene Targets....................................... 7
2.6 Selection of Gene Targets Following Termination of Research
Term .......................................................... 8
3. Research Management Committee; Alliance Directors;
Dispute Resolution................................................... 8
3.1 Research Management Committee.................................... 8
3.2 RMC Meetings..................................................... 9
3.3 Alliance Directors............................................... 9
3.4 Dispute Resolution............................................... 9
4. Patents, Know-How Rights And Inventions............................... 9
4.1 Ownership of Inventions.......................................... 9
4.2 Rights to Gene Logic Technology, Gene Logic Software and
Research Database............................................... 9
4.3 Rights to Improvements to Gene Logic Technology and Gene
Logic Software................................................... 10
4.4 Patent Protection................................................ 10
4.5 Infringement by Third Parties.................................... 11
4.6 Allegations of Infringement by Third Parties..................... 11
4.7 Independent Efforts.............................................. 12
5. Licenses............................................................... 12
5.1 Research Database and Software License to P&GP.................... 12
5.2 Licenses to Gene Logic............................................ 13
5.3 Gene Target License to P&GP....................................... 13
5.4 P&GP Right of First Negotiation .................................. 13
5.5 Gene Logic Right of First Negotiation ............................ 14
ii.
TABLE OF CONTENTS
(CONTINUED)
Page
6. Diligence and Gene Target License Termination......................... 14
6.1 Diligence........................................................ 14
7. Reporting Obligations................................................. 15
7.1 Information and Reports Concerning the Research Program.......... 15
7.2 Diligence Reports................................................ 16
8. Collaboration Expansion Options....................................... 16
9. Payments and Royalties................................................ 16
9.1 Research Reimbursement Payments to Gene Logic.................... 16
9.2 Technology Access Payment to P&GP................................ 17
9.3 Gene Target Fees................................................. 17
9.4 Royalties Payable by P&GP........................................ 17
9.5 Currency of Payment.............................................. 18
9.6 Payment and Reporting............................................ 19
9.7 Records and Audits............................................... 19
10. Milestones............................................................ 19
10.1 Milestones for Therapeutic Products and Protein Products......... 19
10.2 Milestones for Diagnostic Products............................... 20
10.3 Payment of Milestones............................................ 20
11. Confidentiality and Security.......................................... 20
11.1 Security of Research Database.................................... 20
11.2 Confidentiality.................................................. 21
11.3 Permitted Disclosures............................................ 22
11.4 Publicity........................................................ 22
11.5 Publication...................................................... 22
12. Representations And Warranties........................................ 23
12.1 Legal Authority.................................................. 23
12.2 Valid Licenses................................................... 23
12.3 No Conflicts..................................................... 23
12.4 Disclaimer....................................................... 23
13. Term; termination..................................................... 24
13.1 Term............................................................. 24
iii.
TABLE OF CONTENTS
(CONTINUED)
Page
13.2 Termination for Breach.......................................... 24
13.3 Effect of Bankruptcy............................................ 25
13.4 Remedies........................................................ 25
14. Arbitration........................................................... 25
15. General Provisions.................................................... 26
15.1 Mutual Indemnification........................................... 26
15.2 Assignment....................................................... 26
15.3 Change of Control................................................ 26
15.4 Non-Waiver....................................................... 27
15.5 Governing Law.................................................... 28
15.6 Partial Invalidity............................................... 28
15.7 Notice........................................................... 28
15.8 Headings......................................................... 28
15.9 No Implied Licenses or Warranties................................ 29
15.10 Force Majeure................................................... 29
15.11 Survival........................................................ 29
15.12 Entire Agreement................................................ 29
15.13 Amendments...................................................... 29
15.14 Independent Contractors......................................... 29
15.15 Counterparts.................................................... 30
iv.
TARGET DISCOVERY COLLABORATION
AND LICENSE AGREEMENT
This Target Discovery Collaboration And License Agreement ("Agreement") is
made as of May 27, 1997, by and between Gene Logic inc., a Delaware corporation
("Gene Logic"), located at 00000 Xxx Xxxxxxxx Xxxx, Xxxxxxxx, Xxxxxxxx 00000 and
Procter & Xxxxxx Pharmaceuticals, Inc. ("P&GP"), an Ohio corporation, having a
place of business at 0000 Xxxxx-Xxxxxxxxxx Xxxx, Xxxxx, Xxxx 00000.
Witnesseth:
Whereas, Gene Logic has developed technologies and know-how with respect to
high throughput analysis of gene expression and gene regulation for use in the
identification of gene targets and the discovery of pharmaceutical and
diagnostic products;
Whereas, P&GP is a company engaged in the development and commercialization
of pharmaceutical and diagnostic products;
Whereas, P&GP and Gene Logic wish to enter into a collaborative effort
directed toward the development of a Research Database (as defined herein) to
identify genes associated with the onset and progression of heart failure and
ischemic cardiomyopathies (the "Collaboration"); and
Whereas, the parties intend to use the genes so identified to discover,
develop and market human pharmaceutical and diagnostic products.
Now, Therefore, in consideration of the foregoing premises and the mutual
promises, covenants and conditions contained herein, Gene Logic and P&GP agree
as follows:
1. Definitions.
The following capitalized terms shall have the meanings indicated for
purposes of this Agreement:
1.1 "Affiliate" shall mean any corporation, association or other entity
which directly or indirectly controls, is controlled by or is under common
control with the party in question. As used in this definition of "Affiliate,"
the term "control" shall mean direct or indirect beneficial ownership of more
than 50% of the voting or income interest in such corporation or other business
entity.
1.
1.2 "Agreement Term" shall mean the period from the Effective Date until,
with respect to each Product, the expiration of the last royalty obligation owed
by P&GP to Gene Logic with respect to such Product, or until this Agreement is
otherwise terminated pursuant to its terms.
1.3 "Alliance Director" shall have the meaning set forth in Section 3.3.
1.4 "cDNA" shall mean a DNA copy of a mRNA, including, without
limitation, all cDNA clones and cDNA templates derived from a given gene
transcript and its corresponding coding sequence, including the full length
sequence.
1.5 "cDNA Sequence Analysis" shall mean all sequence information from all
cDNA templates derived from the same gene within a given cDNA library.
1.6 "Commercialization Field" shall mean the development or
commercialization of Products for the prevention, treatment or diagnosis of
Heart Failure and ischemic cardiomyopathies in humans and other animals.
1.7 "Control" shall mean possession of the ability to grant the licenses
or sublicenses as provided for herein without violating the terms of any
agreement or other arrangement with any Third Party.
1.8 "Diagnostic Product" shall mean any product or service or combination
thereof used for the diagnosis, prognosis and/or monitoring of progression of
any disease or disorder in humans and other animals which is developed
utilizing, or is comprised of, any Gene Target or which incorporates any Gene
Target DNA or RNA sequence, other than a Protein Product.
1.9 "Drug Approval Application" shall mean an application for Regulatory
Approval required before commercial sale or use of a Product.
1.10 "Effective Date" shall mean the date of this Agreement first written
above.
1.11 "FDA" shall mean the United States Food and Drug Administration.
1.12 "Field" shall mean research, discovery and characterization of genes
associated with the onset and progression of Heart Failure and ischemic
cardiomyopathies through the application of bioinformatics and genomic
technologies to analyze Samples, and the use of such genes for the development
of Products. As used herein, the term "genomic technologies" shall mean,
without limitation, technologies for the analysis of gene expression and gene
regulation, hybridization array techniques, high speed sequencing and generation
of expressed sequence tags.
2.
1.13 "Further Research and Development" shall have the meaning set forth
in Section 2.5.
1.14 "Gene Product" shall mean all partial cDNAs, DNAs, genes, full length
cDNAs corresponding thereto and proteins encoded therefrom.
1.15 "Gene Target" shall have the meaning set forth in Section 2.5.
1.16 "Gene Logic Software" shall mean Gene Logic's software programs for
the analysis of gene expression and gene regulation and the identification and
prioritization of gene targets, including all software programs and analysis
tools that are Controlled by Gene Logic as of the Effective Date or during the
Research Term.
1.17 "Gene Logic Technology" shall mean (i) all discoveries, inventions,
information, data, know-how, trade secrets and materials (whether or not
patentable) that are Controlled by Gene Logic as of the Effective Date or during
the Research Term, including without limitation, the Research Database, Gene
Logic's READS-TM- and MUST-TM- technologies and its Gene Express-TM- database
and (ii) all intellectual property rights of Gene Logic covering the foregoing.
1.18 "Heart Failure" shall mean the inability of the heart to maintain a
circulation sufficient to meet the needs of the body.
1.19 "IND" shall mean an Investigational New Drug Application to the FDA
to commence human clinical testing of a Product, as defined by the FDA, or the
equivalent application in any other Major Market.
1.20 "Invention(s)" shall have the meaning set forth in Section 4.1.
1.21 "Major Market" shall mean the European Union or any one or more of
the following countries: the United States, Canada, United Kingdom, France,
Germany, Italy or Japan.
1.22 "NDA" shall mean a New Drug Application or Product License
Application, as appropriate, and all supplements filed pursuant to the
requirements of the FDA, including all documents, data and other information
concerning Products which are necessary for or included in FDA approval to
market a Product, or the equivalent application in any other Major Market.
1.23 "Net Sales" shall mean the gross invoices delivered by P&GP or its
Affiliates or sublicensees, as appropriate, for the sale of a Product, less the
following deductions:
3.
(1) Prompt payment or other trade or quantity discounts actually
allowed and taken in such amounts as are customary in the trade;
(2) Amounts repaid or credited by reason of timely rejections or
returns;
(3) Any sales or value-added taxes or any other taxes measured by
the amount of sales or gross receipts due on the sale of a Product; and
(4) Allowances for bad debt to the extent such amounts were
previously invoiced and included in Net Sales for royalty purposes and were
subsequently actually written off by P&GP; and
(5) Rebates or discounts actually allowed and taken by government
or other health care organizations, national or other health insurance schemes,
Medicare and Medicaid and the like, state-based or other formularies and managed
care organizations and discounts actually allowed and taken for special
purchases made by hospitals or clinics.
Notwithstanding the foregoing, amounts received by such party or its
Affiliates for the sale of Products among such party and its Affiliates whether
for their internal use or for resale or other disposition will not be included
in the computation of Net Sales hereunder.
1.24 "Patent Right(s)" shall mean, with respect to Gene Logic or P&GP,
all United States and foreign patents (including all reissues, extensions,
confirmations, registrations, re-examinations, and inventor's certificates) and
patent applications (including, without limitation, all substitutions,
continuations, continuations-in-part and divisionals thereof) owned or
Controlled by Gene Logic or P&GP at any time during the Agreement Term.
1.25 "Product" shall mean a Therapeutic Product, Protein Product, or
Diagnostic Product, as applicable.
1.26 "Protein Product" shall mean any product for the prevention or
treatment of any disease or disorder in humans and other animals which
incorporates a protein or peptide (excluding peptides discovered through
screening of Gene Targets) encoded by the full, partial or mutated RNA or DNA
sequence corresponding to a Gene Target RNA or DNA sequence, in any dosage form
for delivery by any route of administration.
1.27 "Regulatory Approval" shall mean (i) approval of an NDA or comparable
applicable filing by the FDA permitting commercial sale of a Product and (ii)
any comparable approval permitting commercial sale of a Product granted by
applicable authorities in any other Major Market.
4.
1.28 "Research Database" shall mean the database created by Gene Logic
using the Gene Logic Technology pursuant to the Research Plan. The Research
Database shall contain data derived from experiments conducted with respect to
the Gene Products identified by Gene Logic pursuant to the Research Program,
including all derivative materials of the Samples and all cDNA sequences,
partial cDNAs and their corresponding full-length cDNAs and cDNA Sequence
Analysis.
1.29 "Research Management Committee" or "RMC" shall have the meaning set
forth in Section 3.1.
1.30 "Research Plan" shall have the meaning set forth in Section 2.1.
1.31 "Research Program" shall mean that program of research performed by
the parties in the Field pursuant to Section 2.
1.32 "Research Term" shall mean the period commencing on the Effective
Date and ending upon the last day of Stage II, subject to extension or earlier
termination as set forth herein.
1.33 "Samples" shall mean tissue samples supplied by P&GP to Gene Logic
for analyses pursuant to the Research Plan.
1.34 "Scientific FTE" shall mean the equivalent of a full-time
researcher's or program manager's work time expended on activities pursuant to
the Research Plan over a 12 month period (including normal vacations, sick days
and holidays).
1.35 "Stage I" shall mean the initial phase of the Research Program and
shall commence as of the Effective Date and extend until the earlier of (i)
the completion by Gene Logic of the READS-TM- analysis of [***] Samples, or
(ii) 18 months from the Effective Date.
1.36 "Stage II" shall mean the second phase of the Research Program,
commencing on the day following the last day of Stage I and extending until
the third anniversary thereof. Stage II may be extended upon mutual
agreement of the parties, as provided in Section 2.4(a).
1.37 "Therapeutic Product" shall mean any product for the prevention or
treatment of any disease or disorder in humans and other animals in any dosage
form by any route of administration, which product incorporates as an active
ingredient a molecule, compound or other agent that (a) is discovered utilizing,
in whole or in part, a Gene Target, whether or not during the Research Term, or
(b) was identified prior to the Effective Date but the utility of which is
discovered utilizing, in whole or in part, a Gene Target, whether or not during
the Research Term, excluding any Diagnostic Product and
5.
CONFIDENTIAL TREATMENT REQUESTED
any Protein Product. For example, "Therapeutic Product" expressly includes any
gene therapy product or antisense product which consists of any full, partial or
mutated RNA or DNA sequence corresponding to, or complementary to a Gene Target
RNA or DNA sequence (a "Biological Therapeutic Product").
1.38 "Third Party" shall mean any party other than P&GP or Gene Logic or
an Affiliate of either of them.
1.39 "Utility" of a target shall mean when the complete cDNA sequence is
available and the corresponding clone is characterized; the recombinant protein
corresponding to the cDNA has been expressed and is purified; and manipulation
of the expression or activity of the molecular target modulates heart function
in an animal model.
2. Research Program.
2.1 Undertaking and Scope. During the first 30 days after the Effective
Date, the parties shall work together to develop a plan for the creation and use
of the Research Database (a "Research Plan") by the parties. The Research
Management Committee will review and approve or modify the general direction of
such Research Plan. The Research Plan shall include such correspondence and
other material of the parties documenting the parties' work to create the
Research Database. At least 90 days before each anniversary of the Effective
Date during the Research Term, the parties shall propose to the RMC a Research
Plan for the subsequent year's work under the Research Program. The RMC shall
review, modify, if appropriate, and amend the Research Plan. Each party agrees
to use all reasonable efforts to perform the activities detailed in the Research
Plan, in a professional and timely manner.
2.2 Personnel and Resources. During the Research Term, each party
agrees to commit the personnel, consultants, facilities, expertise,
technology and other resources necessary to perform its obligations under
the Research Plan. During Stage I of the Research Term, Gene Logic shall
commit no fewer than [***] Scientific FTEs. During Stage II of the Research
Term, P&GP and Gene Logic will each maintain the number of Scientific FTEs
devoted to cooperative work as are required under the Research Plan; provided
that such research support at Gene Logic shall not be fewer than [***]
Scientific FTEs or at such lower level as the parties may mutually agree
taking into account the work to be accomplished pursuant to the Research
Plan. P&GP will provide funding to support Gene Logic's performance of its
obligations under the Research Plan as set forth in Section 9.1(c).
2.3 Establishment of Link to Research Database. During the 30 days after
the Effective Date, the parties shall work together to establish a secure
internet link to the
6.
CONFIDENTIAL TREATMENT REQUESTED
Research Database at P&GP and Gene Logic will make a representative available
at P&GP's facility to assist in such process. In the event that access to the
link to the Research Database is disrupted for a period of one working day or
more, other than due to the fault of P&GP, then the period during which P&GP
shall have access to the Research Database under Section 5.1 shall be
commensurately extended for a period equal to the number of full working days
during which such access was disrupted.
2.4 Term of the Research Program.
(a) Work under the Research Program will commence as of the
Effective Date and, unless terminated earlier pursuant to the terms of this
Agreement or extended by mutual agreement of the parties, will terminate upon
expiration of the Research Term. The parties may extend Stage II of the
Research Term for additional one year periods by mutual written consent. The
Research Term may be terminated by P&GP upon expiration of Stage I with six
months' prior written notice to Gene Logic, or at any time subsequent to the
expiration of Stage I as long as P&GP has provided six months' prior written
notice to Gene Logic; provided, however, that both parties shall be obligated
to continue all Research Program studies ongoing at the time of such written
notice until the effective date of such termination. Upon early termination
by P&GP of the Research Term pursuant to the preceding sentence, Gene Logic
shall return to P&GP any Samples which have not been analyzed, but shall
retain all derivative materials of Samples previously analyzed. Gene Logic
shall not be entitled to terminate the Research Term during Stage I so long
as P&GP has made all required payments to Gene Logic during Stage I.
(b) If the Research Term is terminated by P&GP as provided in
Section 2.4(a), P&GP may elect to recommence the Research Program for up to
two additional one year periods of time (each, an "Additional Research
Program Year") by notifying Gene Logic of its election at least 90 days prior
to either (i) the first anniversary of the termination of the Research Term
or (ii) the expiration of the first Additional Research Program Year, as
applicable, subject to P&GP's payment to Gene Logic, at the time such notice
is provided, of the amounts set forth in Sections 9.1(b) and 9.1(c) to fund
the research to be performed under the Research Program during any such
Additional Research Program Year.
2.5 Selection of Gene Targets. Under the Research Program, the parties
will use reasonable efforts consistent with their respective obligations under
the Research Plans to identify Gene Products from Samples [***] as
potential targets within the Field. P&GP shall select certain of such Gene
Products as targets for further development of pharmaceutical and diagnostic
products using information obtained from the Research Database created by Gene
Logic pursuant to the Research Plan and the application of the Gene Logic
Software and other information available to P&GP,
7.
CONFIDENTIAL TREATMENT REQUESTED
including, without limitation, through public DNA sequence databases and
scientific publications. Any Gene Product identified in the Research Database
which P&GP uses in Further Research and Development (as defined below) shall be
a "Gene Target." Based upon P&GP's standard, internal research and development
criteria, P&GP will, in its sole discretion based upon Utility in Heart Failure,
decide whether to commence Further Research and Development with regard to a
particular Gene Product. P&GP shall notify Gene Logic in writing prior to using
any Gene Target in Further Research and Development and make the payment
described in Section 9.3. For purposes of this Agreement, "Further Research and
Development" of a Gene Target as (i) a Therapeutic Product will include the
[***] of (a) [***] or (b) [***]; (ii) a Protein Product will include the
[***]; and (iii) a Diagnostic Product will include the [***].
2.6 Selection of Gene Targets Following Termination of Research Term. If
P&GP elects to pursue a Gene Target in Further Research and Development within
[***] following expiration of the Research Term, P&GP agrees to notify Gene
Logic in writing and make the payment described in Section 9.3 prior to using
such Gene Target in Further Research and Development. P&GP will be obligated to
make the payments set forth in Sections 9.3, 9.4 and 10 with regard to such Gene
Target.
3. Research Management Committee; Alliance Directors; Dispute
Resolution.
3.1 Research Management Committee. Promptly after the Effective Date,
P&GP and Gene Logic will each appoint three representatives to a research
management committee (the "Research Management Committee" or "RMC"). Attached
as Schedule 3.1 is a list of the representatives the parties intend to appoint
to the RMC. Xxxxx Xxxxxxxxxxx, Ph.D. will serve as chairman of the RMC for the
initial 12 months following the Effective Date. Thereafter, chairmanship will
rotate between a P&GP member and a Gene Logic member every 12 months. P&GP will
determine the scientific priorities and direction of the work to be performed
under the Research Plan, subject to discussion with Gene Logic. The RMC will
review, direct and supervise all operational and scientific aspects related to
the creation of the Research Database. The duties of the Research Management
Committee shall include approving the Research Plans, monitoring the parties'
progress under the Research Plans and evaluating the means through which P&GP
has access to the Research Database. The Research Management Committee will
meet quarterly, or more frequently if mutually agreed, and will alternate sites
of meetings between Cincinnati, Ohio and Columbia, Maryland. The RMC will
8.
CONFIDENTIAL TREATMENT REQUESTED
otherwise communicate regularly by telephone, facsimile and video conference.
Each party recognizes the importance of the Research Management Committee in the
success of the Collaboration and will use diligent efforts to cause all of its
representatives to such committee to attend all meetings of such committee. A
party may change any of its appointments to the Research Management Committee at
any time upon giving written notice to the other party. Any disputes or
disagreements within the RMC shall be resolved pursuant to Section 3.4.
3.2 RMC Meetings. All committees created hereunder may meet by telephone
or video conference or in person at such times as are agreeable to the members
of each such committee. Attendance at meetings shall be at the respective
expense of the participating parties. The chairman of the RMC shall assure that
agendas and minutes are prepared for each of its meetings. All actions taken
and decisions made by the RMC shall be by unanimous agreement, subject to P&GP's
rights to determine scientific priorities pursuant to Section 3.1. If personal
attendance is not possible for valid reasons, voting by proxy is permissible.
3.3 Alliance Directors. Each party shall designate one of its employees
as an alliance director ("Alliance Director") for all of the activities
contemplated under this Agreement. Such Alliance Directors will be responsible
for the day-to-day coordination of the performance of the Research Program and
will serve to facilitate communication between the parties with respect thereto.
Such Alliance Directors shall be experienced in managing research projects
relevant to the Research Program.
3.4 Dispute Resolution. Disputes or disagreements between the parties
arising hereunder will be referred to the Research Management Committee. If the
RMC is unable to resolve, after 30 days, a dispute regarding any issue presented
to it or arising in it, such dispute will be referred to the Chief Executive
Officer of Gene Logic and the Director, Research of P&GP for good faith
resolution, for a period of 90 days. If such dispute is not resolved by the end
of such 90-day period, then such issue shall be submitted for resolution through
arbitration within 30 days after either party requests arbitration, according to
the terms set forth in Section 14.
4. Patents, Know-How Rights And Inventions.
4.1 Ownership of Inventions. Except as otherwise set forth herein,
ownership of any inventions (whether or not patentable) that are conceived,
generated or reduced to practice during the course of the Research Program
("Inventions") shall be determined in accordance with United States laws of
inventorship.
4.2 Rights to Gene Logic Technology, Gene Logic Software and Research
Database. Notwithstanding the foregoing, subject to the grant of intellectual
property
9.
rights to P&GP under the non-exclusive or exclusive licenses granted under
Section 5, Gene Logic shall be entitled to all rights to the Gene Logic
Technology, Gene Logic Software and the Research Database, including, but not
limited to, all data and progeny derived from the Samples, all cDNA sequences,
partial cDNAs, and their corresponding full length cDNAs, cDNA Sequence
Analyses, proteins and applications thereof and information relating thereto,
but not including Gene Targets which shall be subject to Section 4.1. P&GP
agrees to grant the license set forth in Section 5.2(b) in order to accomplish
the foregoing. The filing, prosecution and maintenance of patent(s), copyrights
and other proprietary rights directed at the protection of these rights shall be
the responsibility of, and at the discretion of, Gene Logic.
4.3 Rights to Improvements to Gene Logic Technology and Gene Logic
Software. Gene Logic Technology and Gene Logic Software shall also include any
enhancements or improvements to Gene Logic Technology and Gene Logic Software
discovered by either party during the course of the Collaboration. P&GP agrees
to grant the license set forth in Section 5.2(c) in order to accomplish the
foregoing.
4.4 Patent Protection.
(a) Solely Owned Inventions. Subject to Section 4.4(e), any party
that solely owns any patentable Invention shall have the right, at its option
and expense, to prepare, file and prosecute any patent applications with respect
to such Invention and to maintain any patents issued thereon.
(b) Jointly Owned Inventions. Subject to Section 4.4(e), the
parties shall decide which party shall be responsible for preparing, filing and
prosecuting any patent applications with respect to any Invention that is owned
jointly by the parties (a "Joint Invention") and maintaining any patents issued
thereon, using patent counsel reasonably acceptable to the other party; provided
that P&GP will be responsible for preparing, filing and prosecuting patent
applications with respect to Joint Inventions of Gene Targets and maintaining
any patents issued thereon. The parties shall share the out-of-pocket expenses
for such preparation, filing and prosecution.
(c) Cooperation. Each party agrees to cooperate with the party
responsible for the preparation and prosecution of all patent applications on
Inventions specific to the Field and Joint Inventions pursuant to this
Section 4.4 (the "Responsible Party") and in the maintenance of any patents
issued thereon. Such cooperation will include the execution of all documents
necessary or desirable for the Responsible Party to fulfill its obligations
hereunder.
(d) Communication Regarding Patent Protection. The Responsible
Party will prepare, prosecute and maintain (and shall keep the other party
currently
10.
informed of all steps to be taken in such preparation, prosecution and
maintenance of) all Patent Rights which claim an Invention or Joint Invention
with respect to which it is responsible and shall furnish the other party with
copies of such Patent Rights which claim an Invention specific to the Field or
Joint Invention and other related correspondence relating thereto with respect
to which it is responsible to and from governmental patent agencies or other
authorities and permit the other party to offer its comments thereon before the
Responsible Party makes a submission to a governmental patent agency or other
authority which could materially affect the scope or validity of the patent
coverage that may result. The other party shall offer its comments promptly.
(e) Back-Up Rights. If the Responsible Party with respect to an
Invention specific to the Field or any Joint Invention decides to abandon or not
to pursue prosecution of any Patent Right which claims such Invention or Joint
Invention, it shall permit the other party, at its option and expense, to
undertake such obligations. The party not undertaking such actions shall fully
cooperate with the other party and shall provide to the other party whatever
assignments and other documents that may be needed in connection therewith.
(f) Reimbursement for Gene Target Patent Expenses. In the event
that P&GP selects a Gene Target for Further Research and Development and Gene
Logic has incurred patent expenses in connection with such Gene Target, P&GP
shall reimburse Gene Logic for reasonable out-of-pocket expenses incurred by
Gene Logic for protection of the Gene Target in the Field after the Gene Target
is selected for Further Research and Development within 30 days of receipt of
an invoice therefor.
4.5 Infringement by Third Parties. In the event Gene Logic or P&GP
becomes aware of any actual or threatened infringement of any Patent Right of
either party which claims an Invention or Joint Invention, that party shall
promptly notify the other party, and the parties shall (i) promptly discuss how
to proceed in connection with such actual or threatened infringement and (ii)
use their best efforts in cooperating with each other to terminate such
infringement without litigation, as appropriate and commercially reasonable. If
either party commences any actions or proceedings (legal or otherwise) pursuant
to this Section 4.5, it shall prosecute the same vigorously at its expense and
shall not abandon or compromise them or fail to exercise any rights of appeal
unless commercially reasonable to do so without giving the other party the right
to take over the prosecuting party's conduct at such other party's own expense.
4.6 Allegations of Infringement by Third Parties.
(a) The parties acknowledge that, in order to exploit the rights
contained herein, each party may require licenses under third party patent
rights that may be infringed by the use by such party of the rights granted
herein and it is hereby agreed that
11.
it shall be the responsibility of the party requiring such license to satisfy
itself as to the need for such licenses and, if necessary, to obtain such
licenses.
(b) P&GP shall be solely responsible for any threatened or actual
claims for Third Party patent infringement or other Third Party intellectual
property right arising out of the manufacture, use, sale or importation of a
Product sold by P&GP, its Affiliates or sublicensees. Upon receiving notice of
such actual or threatened claims, P&GP shall promptly meet with Gene Logic to
discuss the course of action to be taken to resolve or defend any such
infringement litigation.
4.7 Independent Efforts. A party shall not, during the Research Term and
any period of time extended pursuant to Section 2.4(b) or Section 5.1, conduct,
have conducted or fund any research or discovery activities that are focused
primarily within the Field except pursuant to this Agreement without the prior
written consent of the other party. Attached hereto as Exhibit A is a listing
of research relationships established prior to the Effective Date which,
although not primarily focused in the Field, are exempt from the limitations of
the preceding sentence. During the Research Term, such Exhibit A shall be
updated from time to time as relationships are approved by written consent
pursuant to this Section 4.7.
5. Licenses.
5.1 Research Database and Software License to P&GP. Gene Logic hereby
grants to P&GP an exclusive, worldwide license to use the Research Database,
together with a nonexclusive license to use the Gene Logic Software, in each
case solely for research purposes in the Field to identify Gene Targets
during the Research Term and for one year thereafter. P&GP will have no
right to sublicense to third parties under such rights; and, except for
disclosure to P&GP employees and consultants to the extent permitted under
Section 11.3, shall not provide any Gene Logic Technology to any Third Party
without prior written consent. P&GP may elect to extend the term of the
foregoing exclusive Research Database license and nonexclusive Gene Logic
Software license (the "First Research Database Extension Option") for an
additional one year period (the "Extended Term") by providing written notice
of such election to Gene Logic at least 90 days prior to the date upon which
such exclusive license would otherwise expire and by paying an extension fee
to Gene Logic equal to [***] within 10 working days from the effective date
of such notice. To the extent that P&GP elects to exercise the First
Database Research Option, P&GP may elect to extend the term of the foregoing
exclusive Research Database license and nonexclusive Gene Logic Software
license (the "Second Research Database Extension Option") for an additional
one year period by providing written notice of such election to Gene Logic at
least 90 days prior to expiration of the Extended Term and by paying an
extension fee to Gene Logic equal to [***] within 10 working days from the
effective date of such notice.
12.
CONFIDENTIAL TREATMENT REQUESTED
5.2 Licenses to Gene Logic.
(a) P&GP hereby grants to Gene Logic a nonexclusive, perpetual,
fully-paid, worldwide license to use and analyze the Samples.
(b) P&GP hereby grants to Gene Logic an exclusive, perpetual,
fully-paid worldwide license under its applicable Patent Rights, Inventions and
other intellectual property to any and all rights it may have in the Gene Logic
Technology, Gene Logic Software and the Research Database, including, but not
limited to, all data and progeny derived from the Samples, all cDNA sequences,
partial cDNAs, and their corresponding full length cDNAs, cDNA Sequence
Analyses, Gene Targets outside of the Commercialization Field, proteins and
applications thereof and information relating to the Gene Logic Technology, Gene
Logic Software and the Research Databases, but not including Gene Targets in the
Commercialization Field.
(c) P&GP hereby grants to Gene Logic an exclusive, perpetual,
fully-paid worldwide license under its applicable Patent Rights, Inventions and
other intellectual property to any enhancements or improvements to the Gene
Logic Technology and Gene Logic Software discovered by P&GP during the course of
the Collaboration, including, without limitation, any discoveries and Inventions
related to the function of Gene Targets outside of the Commercialization Field
included in the Research Database, but not including Gene Targets in the
Commercialization Field.
5.3 Gene Target License to P&GP. Subject to the terms and conditions of
this Agreement, Gene Logic hereby grants and agrees to grant to P&GP an
exclusive, worldwide license under Gene Logic's Patent Rights, if any, to use
each Gene Target for which P&GP has paid the fee described in Section 9.3 to
develop, make, have made, use, import, offer for sale and sell (with the right
to sublicense) Products for use in the Commercialization Field.
5.4 P&GP Right of First Negotiation. Gene Logic grants to P&GP, upon
the request of P&GP, a right of first negotation to obtain an exclusive,
worldwide license to use a Gene Target previously licensed to P&GP in the
Commercialization Field in an additional field or fields outside of the
Commercialization Field upon commercially reasonable terms to be negotiated
in good faith by the parties during the [***]-day period following such
request by P&GP; provided, however, that the foregoing shall not apply to any
rights that Gene Logic has previously granted to any Affiliate or Third
Party. In the event the parties are unable to reach agreement on the terms
of such a license within such [***]-day period or to enter into a definitive
license agreement within [***] days following the mutual request by P&GP, the
parties shall have no further obligation under this Section 5.4 with respect
to a license to such Gene Target for use in such additional field or fields.
13.
CONFIDENTIAL TREATMENT REQUESTED
5.5 Gene Logic Right of First Negotiation. P&GP shall provide at
least [***] days' prior written notice of its intent to license rights to any
Protein Product or Biologicial Therapeutic Product under this Agreement (a
"Sublicensed Product") that P&GP proposes not to commercialize itself and to
sublicense to a Third Party. P&GP grants to Gene Logic a right of first
negotiation to obtain an exclusive, worldwide license under all Patent Rights
and other intellectual property rights of P&GP to make, have made, use, sell,
offer for sale and import the Sublicensed Product upon commercially
reasonable terms to be negotiated in good faith by the parties. Gene Logic
may exercise such right of first negotiation upon written notice to P&GP
within [***] days after receipt of notice from P&GP. In the event the
parties are unable to reach agreement on the terms of such a license within a
[***]-day period following the notice by Gene Logic or to enter into a
definitive agreement within [***] days following the notice by Gene Logic,
the parties shall have no further obligation under this Section 5.5 with
respect to a license to such Sublicensed Product.
6. Diligence and Gene Target License Termination.
6.1 Diligence.
(a) Gene Logic shall use commercially reasonable and diligent
efforts, consistent with the Research Plan and milestones thereof, to perform
analysis of the Samples utilizing the Gene Logic Technology. For purposes of
this Agreement, "commercially reasonable and diligent efforts" will mean, unless
the parties agree otherwise, those efforts consistent with the exercise of
prudent scientific and business judgment, as applied to other research efforts
and to products of similar scientific and commercial potential within such
party's relevant research programs and product lines.
(b) P&GP shall use commercially reasonable and diligent efforts to
conduct active, ongoing research activities utilizing the Research Database.
(c) Without limiting the foregoing, P&GP (or its Affiliates or
sublicensees) shall use commercially reasonable and diligent efforts to evaluate
the Gene Targets and to develop and commercialize Products in the
Commercialization Field. P&GP (or its Affiliates or sublicensees) shall be
deemed to have used commercially reasonable and diligent efforts with regard to
the Gene Targets if it is actively engaged in a development process of one or
more Gene Targets in at least one of the following activities: (i) [***];
(ii) [***]; or (iii) [***]. Gene Logic may provide [***] written notice to
P&GP if in its opinion, P&GP is not using commercially
reasonable and diligent efforts with
14.
CONFIDENTIAL TREATMENT REQUESTED
regard to the Gene Targets, whereupon the Alliance Directors shall meet within
said [***] period to determine what actions, if any, are necessary or
appropriate to rectify the situation. Upon recommendation by the Alliance
Directors, P&GP shall use commercially reasonable and diligent efforts to take
such recommended actions within [***] after receipt of said recommendation.
In the event that, in the determination of Gene Logic, P&GP has not taken steps
to accomplish such actions recommended by the Alliance Directors within such
[***] period, the parties agree to hold a meeting, attended by individuals with
decision-making authority, to attempt in good faith to negotiate a resolution of
the dispute. If, within [***] after such meeting, the parties have not
succeeded in negotiating a resolution of the dispute, then such dispute shall be
submitted for resolution through arbitration, according to the terms set forth
in Section 14. In the event that such arbitration results in a determination
that P&GP did not use commercially reasonable and diligent efforts with regard
to Gene Targets, then (i) Gene Logic shall be entitled to terminate the
exclusive license granted pursuant to Section 5.3 with respect to such Gene
Target, on a worldwide basis, and (ii) P&GP shall automatically grant to Gene
Logic an exclusive, perpetual, fully-paid worldwide license under its applicable
Patent Rights, Inventions and other intellectual property to any and all rights
it may have in the Gene Targets in the Commercialization Field.
(d) In addition, in the event that P&GP elects not to pursue
exploitation of any Gene Target or development or commercialization of any
Product subject to this Agreement for any reason, P&GP shall promptly notify
Gene Logic thereof, and, upon such notice, (i) the exclusive license granted
pursuant to Section 5.3 with respect to such Gene Target on a worldwide basis
will be terminated, and (ii) P&GP shall automatically grant to Gene Logic an
exclusive, perpetual, fully-paid worldwide license under its applicable Patent
Rights, Inventions and other intellectual property to any and all rights it may
have in the Gene Target in the Field. In the event P&GP automatically grants
the license described in this Section 6.1(d)(ii), the parties shall negotiate a
commercially reasonable royalty rate to be paid by Gene Logic based upon the
value of P&GP's Patent Rights covering such Gene Target.
7. Reporting Obligations.
7.1 Information and Reports Concerning the Research Program. All
information, technology or inventions specific to the Field made by either party
in the course of the Research Program will be promptly disclosed to the other,
with significant discoveries or advances being communicated as soon as
practicable after such information is obtained or its significance is
appreciated. The RMC shall produce a written report at least quarterly
presenting a meaningful summary of the activities performed under this
Agreement; including, without limitation, a summary of the number of Samples
analyzed and consideration of Gene Logic's performance compared to the
milestones set forth in the Promissory Note issued by Gene Logic pursuant to
Section 9.2.
15.
CONFIDENTIAL TREATMENT REQUESTED
7.2 Diligence Reports. P&GP hereby agrees to keep Gene Logic informed on
a reasonable basis of its efforts to select Gene Targets and to develop Products
in the Commercialization Field, and to provide written reports to Gene Logic on
a semi-annual basis (the "Diligence Reports"). The Diligence Reports shall
provide, as applicable, the following information: (i) a listing of the Gene
Products which P&GP has identified as prospects for Further Research and
Development, (ii) P&GP's progress toward selection of particular Gene Products
for Further Research and Development, (iii) P&GP's plans for Further Research
and Development with regard to selected Gene Targets, and (iv) P&GP's progress
in screening, pre-clinical or clinical development for Gene Targets.
8. Collaboration Expansion Options.
From the Effective Date and prior to the completion of Stage I (the
"Expansion Option Period"), P&GP shall have options to enter collaborations with
Gene Logic in the areas of [***] (the "[***] Option") and [***] (the "[***]
Option"), upon the same terms and conditions contained in this
Agreement, including the research funding, milestone payments and royalty
provisions set forth in Sections 9 and 10 and in the aggregate commensurate with
the research and development funding of Gene Logic by P&GP in the [***]
this Agreement. In addition, P&GP shall have the option to extend for one year
the term of the Expansion Option Period for the [***] Option or the [***] Option
with payment of [***] for each option extended. In the event that P&GP does
not exercise the [***] Option or the [***] Option prior to the expiration of the
applicable Expansion Option Period, then Gene Logic shall thereafter be free to
grant rights to a Third Party in the areas of [***] or [***], as applicable.
In the event P&GP does exercise the [***] Option or the [***] Option, the
parties will enter an agreement with terms consistent with the requirements of
this Section 8 in the areas of [***] or [***], as applicable.
9. Payments and Royalties.
9.1 Payments to Gene Logic.
(a) P&GP shall pay Gene Logic $3,000,000 within five business days
of the Effective Date in connection with the licenses granted under this
Agreement and to defray research costs associated with the Research Plans
during Stage I, including, but not limited to, creating the Research Database,
analyzing Samples pursuant to the Research Plans and development of Gene
Logic Technology and upgrades thereof during the Research Term.
16.
CONFIDENTIAL TREATMENT REQUESTED
(b) P&GP shall pay Gene Logic [***] upon the commencement of
Stage II and on each anniversary of the commencement of Stage II in connection
with the licenses granted under this Agreement and to defray research costs
associated with the Research Plans during Stage II, including, but not limited
to, creating the Research Database, analyzing Samples pursuant to the Research
Plans and development of Gene Logic Technology and upgrades thereof during the
Research Term. If Stage II of the Research Program ends on an anniversary of
the commencement of Stage II (or within one day thereof) then no [***]
payment shall be due on such anniversary.
(c) During Stage II, P&GP shall provide Gene Logic with financial
support for the Research Program for Gene Logic's Scientific FTEs at a rate of
[***] for 1997 per Scientific FTE. The FTE payment rate payable pursuant to
this Section 9.1(c) shall be reevaluated annually and adjusted in proportion to
the percentage increase for the prior year in the Consumer Price Index of all
urban consumers as provided by the U.S. Bureau of Labor Statistics. The number
of Scientific FTEs for each year of Stage II will be set forth in the applicable
Research Plan; provided that such research funding shall not support fewer than
[***] Scientific FTEs ([***] for 1997) in any one year period commencing with
the start of Phase II or any anniversary thereof (each, a "Program Year") or at
such lower level as the parties may mutually agree taking into account the work
to be accomplished pursuant to the Research Plan.
(d) The research funding to be provided pursuant to Section 9.1(c)
shall be made in four quarterly payments during each Program Year. Such
payments shall be payable in arrears and shall be made within 30 days from the
receipt of an invoice therefor.
9.2 Technology Access Payment to P&GP. On the Effective Date, Gene Logic
shall execute a Promissory Note payable to P&GP in the amount of $2,000,000, in
the form attached as Exhibit B. Except as expressly provided in the Promissory
Note, P&GP shall not be entitled to offset any amount owed by Gene Logic under
such Promissory Note against any payment owed by P&GP to Gene Logic hereunder.
9.3 Gene Target Fees. P&GP shall pay [***] to Gene Logic for each
Gene Target which P&GP selects for Further Research and Development pursuant to
Section 2.5 within 30 days following notification thereof.
9.4 Royalties Payable by P&GP. P&GP will pay Gene Logic royalties at the
following rates on Net Sales of each Product sold by P&GP, its Affiliates and
sublicensees pursuant to this Agreement.
17.
CONFIDENTIAL TREATMENT REQUESTED
Therapeutic Protein
Annual Worldwide Net Sales Product Product
--------------------------- ------------ --------
[***]............................................. [***] [***]
[***]............................................. [***] [***]
[***]............................................. [***] [***]
[***]............................................. [***] [***]
P&GP shall pay Gene Logic a [***] royalty on annual Net Sales of each
Diagnostic Product sold by P&GP, its Affiliates and sublicensees pursuant to
this Agreement.
Net Sales shall be calculated on a calendar year basis. A sample royalty
calculation is set forth on Schedule 9.4.
P&GP shall remain responsible for all royalty payments payable to Gene
Logic pursuant to this Section 9 whether P&GP or its Affiliates or sublicensees
generate Net Sales.
In the event that P&GP obtains a license under any third party patent
rights to a Gene Target required to make, have made, use, sell, offer to sell or
import any Protein Product or Biological Therapeutic Product, the royalty
payable to Gene Logic under this Section 9.4 for any payment period will be
reduced by an amount equal to [***] of royalties actually paid by P&GP to such
third party for such period; provided that, in no event shall the royalty
payable to Gene Logic be reduced to less than [***] of the applicable royalty
rate set forth above for such period.
Royalties shall be payable on all Net Sales of any Product for the period
of time commencing on the date such Product is first sold commercially in any
country and ending, on a country-by-country basis, upon the later of (a) 10
years from the date of such first commercial sale of such Product in such
country, or (b) the expiration of the last to expire of P&GP's Patent Rights
covering such Product in such country; provided that, if there are multiple
Products derived from a single Gene Target, then the maximum amount of time
that royalties will be payable upon Products will be 20 years from the
date of filing the patent for the first Product or the filing of any
continuation or CIP thereof.
9.5 Currency of Payment. All payments to be made under this Agreement
shall be made in United States dollars in the United States to a bank account
designated by Gene Logic. All amounts payable by P&GP to Gene Logic pursuant to
this Section 9 shall be non-refundable and non-creditable against any other
payments due under this Agreement (except as expressly provided in the
Promissory Note executed pursuant to Section 9.2). Royalties shall be
determined based on Net Sales in the currency of the country in which they are
earned converted to its equivalent in United States currency. The buying rates
involved for the currency of the United States into which the currencies
involved are being exchanged shall be the one quoted by The Wall Street Journal
(or if not available, by Citibank (or its successor in interest) in New York,
New York) at the
18.
CONFIDENTIAL TREATMENT REQUESTED
close of business on the last business day of the quarterly period in which the
royalties were earned shall be used to determine any such conversion.
9.6 Payment and Reporting. All amounts payable by P&GP to Gene Logic
pursuant to this Section 9 shall be made by wire transfer pursuant to the
instructions set forth on Schedule 9.6. By March 1 of each calendar year, P&GP
will communicate to Gene Logic a forecast of Net Sales for each Product to be
sold pursuant to this Agreement in a given calendar year on a country-by-country
basis, including a calculation of the royalty amount payable for each Product
using such forecast (the "Forecast Royalty Amount") starting the quarter in
which the first commercial sale is made for such Product. Gene Logic will issue
an invoice to P&GP on the first day of the months of April, July and October for
an amount equal to 25% of the Forecast Royalty Amount, payable within 30 days
after the date of such invoice. Within 30 days after the end of each calendar
year, P&GP will communicate to Gene Logic the actual Net Sales for the Products
sold pursuant to this Agreement for such calendar year, including a calculation
of the royalty amount payable on such actual Net Sales (the "Actual Royalty
Amount"). Gene Logic will promptly issue either an invoice to P&GP for the
amount, if any, by which the Actual Royalty Amount exceeds all royalty payments
already made for such calendar year, payable within 30 days after the date of
such invoice or a credit to be applied to the next quarter if an overpayment has
occurred.
9.7 Records and Audits. P&GP shall keep complete and accurate records
pertaining to the sale or other disposition of Products sold by P&GP, its
Affiliates and sublicensees pursuant to this Agreement in sufficient detail to
permit Gene Logic to confirm the accuracy of all payments due hereunder. Gene
Logic shall have the right to cause an independent, certified public accountant
reasonably acceptable to P&GP to audit such records and audit work pages as
presented by Deloitte & Touche to confirm Net Sales and royalty and other
payments for the preceding year. Such audits may be exercised during normal
business hours once a year upon at least 30 working days prior written notice to
P&GP. Gene Logic shall bear the full cost of such audit unless such audit
discloses a variance of more than 5% from the amount of the Net Sales or
royalties or other payments due under this Agreement. In such case, P&GP shall
bear the full cost of such audit and Gene Logic shall have the right to audit
all prior years not previously audited, limited to the 3 previous years.
10. Milestones.
10.1 Milestones for Therapeutic Products and Protein Products. P&GP
shall pay Gene Logic the following amounts with respect to each Therapeutic
Product and each Protein Product sold by P&GP, its Affiliates and sublicensees
pursuant to this Agreement with respect to which each stated milestone is
achieved, within 30 days following the achievement of such milestone:
19.
(a) [***] (subject to the limitations
set forth below)................................... [***]
(b) [***].............................................. [***]
(c) [***].............................................. [***]
(d) [***].............................................. [***]
With regard to amounts payable pursuant to Section 10.1(a), P&GP will not
be obligated to pay Gene Logic additional [***] milestone payments for
subsequent [***].
10.2 Milestones for Diagnostic Products. P&GP shall pay Gene Logic the
following amounts with respect to each Diagnostic Product sold by P&GP, its
Affiliates and sublicensees pursuant to this Agreement with respect to which
each stated milestone is achieved, within 30 days following the achievement
of such milestone:
(a) [***] [***]
(b) [***] [***]
10.3 Payment of Milestones. Milestone payments made under this section
shall be non-refundable and non-creditable against any other payments due
under this Agreement. All such payments shall be made by wire transfer
pursuant to the instructions set forth on Schedule 9.6. Milestone payments
made under this section shall fund in substantial part the research costs
associated with this Agreement.
11. Confidentiality and Security.
11.1 Security of Research Database.
(a) The parties agree that the following additional terms and
conditions apply to the information and data contained in or derived from the
Research Database that is disclosed under the provisions of this Agreement:
(i) P&GP may use the Research Database only for its own
internal use in secure work facilities by authorized personnel and shall not
make any copies of the Research Database.
20.
CONFIDENTIAL TREATMENT REQUESTED
(ii) P&GP will be provided with access to the Research Database
only through a secure, encrypted link to Gene Logic's computer system.
(iii) P&GP will promptly notify Gene Logic of any (i) loss,
theft or unauthorized disclosure of information or data derived from the
Research Database and (ii) unauthorized access to the Research Database.
(iv) Upon termination of the Research Program as provided in
Section 2.5, P&GP shall immediately discontinue use of the Research Database
and of any information or data derived from the Research Database (except for
Gene Targets that are the subject of exclusive licenses as set forth in
Section 5.3), and P&GP shall cooperate with Gene Logic to terminate the
encrypted link to Gene Logic's computer system.
11.2 Confidentiality.
(a) Except as specifically permitted hereunder (including without
limitation all rights granted under Section 5), each party hereby agrees to
hold in confidence and not use on behalf of itself or others all technology,
data, samples, technical and economic information (including the economic
terms hereof), commercialization, clinical and research strategies, know-how
and trade secrets provided by the other party (the "Disclosing Party") from
the date of that certain confidentiality agreement between the parties dated
February 27, 1997 and through the end of the Agreement Term (collectively the
"Confidential Information"), except that the term "Confidential Information"
shall not include:
(i) information that is or becomes part of the public domain
through no fault of the non-Disclosing Party or its Affiliates;
(ii) information that is obtained after the date hereof by the
non-Disclosing Party or one of its Affiliates from any Third Party which is
lawfully in possession of such Confidential Information and not in violation
of any contractual or legal obligation to the Disclosing Party with respect
to such Confidential Information;
(iii) information that is known to the non-Disclosing Party or
one or more of its Affiliates prior to disclosure by the Disclosing Party, as
evidenced by the non-Disclosing Party's written records;
(iv) information that is required to be disclosed to any
governmental authorities or pursuant to any regulatory filings, but only to
the limited extent of such legally required disclosure; and
21.
(v) information which has been independently developed by the
non-Disclosing Party without the aid or use of Confidential Information as
shown by competent written evidence.
(b) The obligations of this Section 11.2 shall survive the
expiration or termination of this Agreement for a period of 10 years.
11.3 Permitted Disclosures. Confidential Information may be disclosed to
employees, agents, consultants or sublicensees of the non-Disclosing Party or
its Affiliates, but only to the extent required to accomplish the purposes of
this Agreement and only if the non-Disclosing Party obtains prior agreement
from its employees, agents, consultants and sublicensees to whom disclosure
is to be made to hold in confidence and not make use of such information for
any purpose other than those permitted by this Agreement. Each party will
use at least the same standard of care as it uses to protect proprietary or
confidential information of its own to ensure that such employees, agents,
consultants or sublicensees do not disclose or make any unauthorized use of
the Confidential Information. Notwithstanding any other provision of this
Agreement, each party may disclose the terms of this Agreement to lenders,
investment bankers and other financial institutions of its choice solely for
purposes of financing the business operations of such party either (i) upon
the written consent of the other party or (ii) if the disclosing party
obtains a signed confidentiality agreement with such financial institution
with respect to such information, upon terms substantially similar to those
contained in this Section 11.
11.4 Publicity. All publicity, press releases and other announcements
relating to this Agreement or the transaction contemplated hereby shall be
reviewed in advance by, and shall be subject to the approval of, both
parties, which approval shall not be unreasonably withheld; provided,
however, that either party may (i) publicize the existence and general
subject matter of this Agreement consistent with previous press releases and
statements without the other party's approval and (ii) disclose the terms of
this Agreement only to the extent required to comply with applicable
securities laws.
11.5 Publication. The parties shall cooperate in appropriate
publication of the results of research and development work performed
pursuant to this Agreement, but subject to the predominating interest to
obtain patent protection for any patentable subject matter. To this end,
prior to any public disclosure of such results, the party proposing
disclosure shall send the other party a copy of the information to be
disclosed, and shall allow the other party 30 days from the date of receipt
in which to determine whether the information to be disclosed contains
subject matter for which patent protection should be sought prior to
disclosure, or otherwise contains Confidential Information of the reviewing
party. The party proposing disclosure shall be free to proceed with the
disclosure unless prior to the expiration of such 30-day period the
non-disclosing party
22.
notifies the other party that the disclosure contains subject matter for which
patent protection should be sought or Confidential Information of the
non-disclosing party, and the party proposing publication shall then delay
public disclosure of the information for an additional period of up to three
months to permit the preparation and filing of a patent application on the
subject matter to be disclosed or for the parties to determine a mutually
acceptable modification to such publication to protect the Confidential
Information of the non-disclosing party adequately. The party proposing
disclosure shall thereafter be free to publish or disclose the information. The
determination of authorship for any paper shall be in accordance with accepted
scientific practice.
12. Representations And Warranties.
12.1 Legal Authority. Each party represents and warrants to the other
that it has the legal power, authority and right to enter into this Agreement
and to perform its respective obligations set forth herein.
12.2 Valid Licenses. P&GP represents and warrants that (i) it has
authority to grant the rights and licenses set forth in this Agreement with
respect to the Samples and all derivative materials of such Samples and (ii)
to the best of P&GP's knowledge, Gene Logic shall have free and clear right
to all derivative materials of such Samples. Gene Logic represents and
warrants that it has authority to grant the rights and licenses set forth in
this Agreement.
12.3 No Conflicts. Each party represents and warrants that as of the
date of this Agreement it is not a party to any agreement or arrangement with
any Third Party or under any obligation or restriction, including pursuant to
its Certificate of Incorporation or By-Laws, which in any way limits or
conflicts with its ability to fulfill any of its obligations under this
Agreement.
12.4 Disclaimer. Except as expressly set forth in this Agreement, EACH
PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE
INFORMATION, MATERIALS, SOFTWARE AND OTHER TECHNOLOGY PROVIDED HEREUNDER WILL
NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF ANY THIRD
PARTY. NEITHER PARTY MAKES ANY WARRANTY OF ANY KIND AS TO THE PATENTABILITY
OF ANY DISCOVERY MADE OR TECHNOLOGY DEVELOPED UNDER THIS AGREEMENT. EACH
PARTY ACKNOWLEDGES THAT THIS AGREEMENT PROVIDES FOR AN INNOVATIVE PROGRAM
UTILIZING NEW TECHNOLOGIES AND THAT NO
23.
WARRANTY IS MADE AS TO THE UTILITY OF ANY INFORMATION, MATERIALS, SOFTWARE OR
OTHER TECHNOLOGY PROVIDED HEREUNDER.
13. Term; termination.
13.1 Term. The term of this Agreement shall commence upon the Effective
Date and shall expire upon the expiration of all royalty obligations set
forth in Section 9.
13.2 Termination for Breach.
(a) Breach by Gene Logic. If Gene Logic breaches a material term
of this Agreement at any time, and has not cured such breach within 60 days
after written notice thereof from P&GP, then P&GP shall have the right to
terminate this Agreement effective upon written notice thereof, whereupon all
rights and obligations of the parties under this Agreement shall terminate
except as set forth in Section 15.11 and subject to the following: (i) the
licenses granted to P&GP under Section 5 shall remain in full force and
effect for so long as P&GP is not in breach of its obligations to Gene Logic
under this Agreement, (ii) the license granted to Gene Logic under Section
5.2(a) shall remain in full force and effect, (iii) the licenses granted to
Gene Logic under Sections 5.2(b) and 5.2(c) shall terminate, (iv) the right
of first negotiation granted to Gene Logic pursuant to Section 5.5 shall
terminate and (v) Gene Logic shall return to P&GP all Confidential
Information of P&GP.
(b) Breach by P&GP. If P&GP breaches a material term of this
Agreement at any time, and has not cured such breach within 60 days (or
within 15 days in the event of a material breach by P&GP of its obligations
to make any payments due pursuant to Sections 9 and 10) after written notice
thereof from Gene Logic, then Gene Logic shall have the right to terminate
this Agreement effective upon written notice thereof, whereupon all rights
and obligations of the parties under this Agreement shall terminate except as
set forth in Section 15.11 and subject to the following: (i) the licenses
granted to Gene Logic under Section 5 shall remain in full force and effect,
(ii) the option to recommence the Research Program pursuant to Section 2.4(b)
shall terminate, (iii) the license granted to P&GP pursuant to Section 5.1
shall terminate (including all options to extend such license), (iv) the
license granted to P&GP pursuant to Section 5.3 shall terminate (v) the right
of first negotiation granted to P&GP pursuant to Section 5.4 shall terminate,
(vi) the [***] Option and the [***] Option granted pursuant to Section 8 shall
terminate, and (vii) P&GP shall return to Gene Logic all Confidential
Information of Gene Logic. In the event of an uncured material breach by P&GP
of its obligations to pay any royalties due and owing with respect to a Product
pursuant to Section 9, if Gene Logic terminates the licenses it has granted to
P&GP pursuant to Section 5 in respect of such Product, at Gene Logic's request,
P&GP shall grant to Gene Logic an exclusive (even as to P&GP) worldwide license
(with the right to
24.
CONFIDENTIAL TREATMENT REQUESTED
sublicense) to such Product, to the extent necessary to make, use or sell
such Product subject to payment of a royalty to P&GP on Net Sales of such
Product (the parties shall negotiate a commercially reasonable royalty rate
to be paid by Gene Logic based upon the value of P&GP's Patent Rights
covering such Product), and shall further assign to Gene Logic all Regulatory
Approvals (to the extent permitted by law) in such countries.
(c) If a dispute arises between the parties relating to the grounds
for the termination under this Section 13.2, the parties agree to hold a
meeting, attended by individuals with decision-making authority, to attempt
in good faith to negotiate a resolution of the dispute. If, within 30 days
after such meeting the parties have not succeeded in negotiating a resolution
of the dispute, then such dispute shall be submitted for resolution through
arbitration, according to the terms set forth in Section 14.
13.3 Effect of Bankruptcy. If, during the Research Term, either party
files a voluntary petition in bankruptcy, is adjudicated a bankrupt, makes a
general assignment for the benefit of creditors, admits in writing that it is
insolvent or fails to discharge within 15 days an involuntary petition in
bankruptcy filed against it, then the Research Term and the entirety of this
Agreement may be immediately terminated by the other party. In addition, in
the event that Gene Logic files a voluntary petition in bankruptcy, is
adjudicated a bankrupt, makes a general assignment for the benefit of
creditors, admits in writing that it is insolvent or fails to discharge
within 15 days an involuntary petition in bankruptcy filed against it, then
the parties hereby acknowledge and agree that P&GP will have right of access
to the Research Database consistent with the terms of this Agreement for
purposes of 11 U.S.C. Section 365(n).
13.4 Remedies. In the event of any breach of any provision of this
Agreement, in addition to the termination rights set forth herein, each party
shall have all other rights and remedies at law or equity to enforce this
Agreement.
14. Arbitration.
14.1 Any controversy arising under or related to this Agreement, and any
disputed claim by either party against the other under this Agreement,
excluding any dispute relating to patent validity or infringement arising
under this Agreement, shall be settled by arbitration in accordance with the
then existing Commercial Arbitration Rules of the American Arbitration
Association.
14.2 Upon request by either party, arbitration will be by a panel of
three arbitrators within 30 days of such arbitration request. Each party
shall select one arbitrator and the third shall be mutually agreed upon in
writing by both parties. In any such arbitration, Gene Logic and P&GP shall
select a panel with relevant experience in
25.
the pharmaceutical industry. Judgment upon the award rendered by the panel
shall be final and nonappealable and may be entered in any court having
jurisdiction thereof.
14.3 The parties shall be entitled to all discovery in like manner as if
the arbitration were a civil suit in the Delaware Superior Court.
14.4 Any arbitration shall be held in Wilmington, Delaware unless the
parties hereto mutually agree in writing to another place.
15. General Provisions.
15.1 Mutual Indemnification. Each party agrees to defend, indemnify and
hold harmless the other party and its Affiliates, employees, agents,
officers, directors and permitted from and against any judgments,
settlements, damages, awards, costs (including attorneys' fees and costs) and
other expenses arising out of any claims, actions or other proceedings by a
third party (collectively a "Claim") arising out of or resulting from the
development, manufacture, use, promotion, marketing, handling, storage or
sale of any Product, except to the extent that such Claim arises out of or
results from the negligence or misconduct of the party claiming a right of
indemnification under this Section 15.1. In the event either party seeks
indemnification under this Section 15.1, it shall inform the other party of a
Claim as soon as reasonably practicable after it receives notice of the
Claim, shall permit the other party to assume direction and control of the
defense of the Claim (including the right to settle the Claim solely for
monetary consideration), and shall cooperate as requested (at the expense of
the other party) in the defense of the Claim. The obligations set forth in
this section shall survive the expiration or termination of this Agreement.
15.2 Assignment. This Agreement shall not be assignable by either party
without the prior written consent of the other party, such consent not to be
unreasonably withheld or delayed, except a party may make such an assignment
without the other party's consent to Affiliates or to a successor to
substantially all of the pharmaceutical business of such party, whether in
merger, sale of stock, sale of assets or other transaction; provided,
however, that in the event of such transaction no intellectual property
rights of any Affiliate or Third Party that is an acquiring party shall be
included in the technology licensed hereunder. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal
representatives and assigns.
15.3 Change of Control.
(a) In the event of a Change in Control, as that term is defined in
Section 15.3(b), of one party under this Agreement (the "Acquired Company")
during the Research Term (as may be extended), then the Acquired Company shall
notify the other party of any such Change of Control as soon as the Change in
Control may publicly be
26.
CONFIDENTIAL TREATMENT REQUESTED
announced. In the event that the Acquired Company is acquired by a Third
Party that (i) in the good faith determination of the Board of Directors
of the other party (the "Electing Company"), is a competitor of the Electing
Company in the Commercialization Field or (ii) has announced its intention
to cease operations of the Acquired Company, then the Electing Company shall
have the right to give notice to the Acquired Company within 60 days after
receipt of the Acquired Company's notification that the Electing Company
elects not to continue the Collaboration (the "Discontinuation Notice").
Within 30 days after receipt of the Discontinuation Notice, determination of
the Change of Control Fee pursuant to Section 15.3(c) will be made and such
Change of Control Fee will be paid to the Electing Company by the Acquired
Party or its acquiror. In addition, in the event that P&GP is the Electing
party, P&GP will continue to have access to the Research Database, on an
exclusive basis solely for research purposes in the field to identify Gene
Targets for one year after the date of payment of the Change of Control Fee
and will have a License under Section 5.3 to Gene Targets selected on or
prior to the end of such one-year period subject to P&GP's obligation to make
all required payments to Gene Logic (or its successor in interest) hereunder.
(b) For purposes of this Agreement, a "Change in Control" of a
company shall be deemed to have occurred in the event of (i) a merger or
consolidation of the company with another corporation, not including any
merger or consolidation if immediately thereafter the stockholders of the
company immediately before such transaction own Shares representing more than
50% of the outstanding voting securities of the surviving corporation (ii) a
sale of shares by the stockholders of the company if immediately thereafter
the stockholders of the Company immediately before such sale own shares
representing 50% or less of the outstanding voting securities of the
surviving corporation, or (iii) a sale of all or substantially all of the
company's assets. Notwithstanding the foregoing, The Procter & Xxxxxx Company
directly or indirectly must have at least 60% of the combined voting power
of P&GP's outstanding voting securities, otherwise there shall be a Change of
Control of P&GP.
(c) The "Change of Control Fee" shall be determined as follows: As
of the date of the Discontinuation Notice the parties shall determine (i) the
[***], and (ii) the [***]. The Change of Control Fee shall be calculated by
subtracting [***] from [***] and multiplying [***].
15.4 Non-Waiver. The waiver by either of the parties of any breach of
any provision hereof by the other party shall not be construed to be a waiver
of any succeeding breach of such provision or a waiver of the provision
itself.
27.
CONFIDENTIAL TREATMENT REQUESTED
15.5 Governing Law. This Agreement shall be construed and interpreted in
accordance with the laws of the State of Delaware other than those provisions
governing conflicts of law.
15.6 Partial Invalidity. If and to the extent that any court or tribunal
of competent jurisdiction holds any of the terms or provisions of this
Agreement, or the application thereof to any circumstances, to be invalid or
unenforceable in a final nonappealable order, the parties shall use their
best efforts to reform the portions of this Agreement declared invalid to
realize the intent of the parties as fully as practicable, and the remainder
of this Agreement and the application of such invalid term or provision to
circumstances other than those as to which it is held invalid or
unenforceable shall not be affected thereby, and each of the remaining terms
and provisions of this Agreement shall remain valid and enforceable to the
fullest extent of the law.
15.7 Notice. Any notice to be given to a party under or in connection
with this Agreement shall be in writing and shall be (i) personally
delivered, (ii) delivered by a nationally recognized overnight courier, (iii)
delivered by certified mail, postage prepaid, return receipt requested or
(iv) delivered via facsimile, with receipt confirmed, to the party at the
address set forth below for such party:
To P&GP: To Gene Logic:
0000 Xxxxx-Xxxxxxxxxx Xxxx 00000 Xxx Xxxxxxxx Xxxx
Xxxxx, Xxxx 00000 Xxxxxxxx, Xxxxxxxx 00000
Attn: Director, Research P&GP
Phone: (000) 000-0000 Phone: (000) 000-0000
Fax: (000) 000-0000 Fax: (000) 000-0000
with a copy to: with a copy to:
Legal Department Xxxxxxxxx X. Xxxx, Esq.
0000 Xxxxx-Xxxxxxxxxx Xxxx Xxxxxx Xxxxxxx XXX
Xxxxx, Xxxx 00000 0000 Xxxxxxxxx Xxxxx, Xxxxx 0000
Xxx Xxxxx, XX 00000
Phone: (000) 000-0000 Phone: (000) 000-0000
Fax: (000) 000-0000 Fax: (000) 000-0000
or to such other address as to which the party has given written notice
thereof. Such notices shall be deemed given upon receipt.
15.8 Headings. The headings appearing herein have been inserted solely
for the convenience of the parties hereto and shall not affect the
construction, meaning or interpretation of this Agreement or any of its terms
and conditions.
28.
15.9 No Implied Licenses or Warranties. No right or license under any
patent application, issued patent, know-how or other proprietary information
is granted or shall be granted by implication. All such rights or licenses
are or shall be granted only as expressly provided in the terms of this
Agreement. Neither party warrants that (i) the Research Program shall achieve
any of the research objectives contemplated by them or (ii) any clinical or
other studies will be successful.
15.10 Force Majeure. No failure or omission by the parties hereto in the
performance of any obligation of this Agreement shall be deemed a breach of
this Agreement nor shall it create any liability if the same shall arise from
any cause or causes beyond the reasonable control of the affected party,
including, but not limited to, the following, which for purposes of this
Agreement shall be regarded as beyond the control of the party in question:
acts of nature; acts or omissions of any government; any rules, regulations,
or orders issued by any governmental authority or by any officer, department,
agency or instrumentality thereof; fire; storm; flood; earthquake; accident;
war; rebellion; insurrection; riot; invasion; strikes; and labor lockouts;
provided that the party so affected shall use its best efforts to avoid or
remove such causes of nonperformance and shall continue performance hereunder
with the utmost dispatch whenever such causes are removed.
15.11 Survival. Sections 4.1, 4.2, 4.3, 5.2, 11.2, 12, 13.2 (including
the provisions described therein that are contemplated to continue following
termination), 14, 15.1, 15.5 and 15.11 shall survive the termination or
expiration of this Agreement.
15.12 Entire Agreement. This Agreement constitutes the entire
understanding between the parties with respect to the subject matter
contained herein and supersedes any and all prior agreements, understandings
and arrangements whether oral or written between the parties relating to the
subject matter hereof.
15.13 Amendments. No amendment, change, modification or alteration of
the terms and conditions of this Agreement shall be binding upon either party
unless in writing and signed by the party to be charged.
15.14 Independent Contractors. It is understood that both parties hereto
are independent contractors and are engaged in the operation of their own
respective businesses, and neither party hereto is to be considered the agent
or partner of the other party for any purpose whatsoever. Neither party has
any authority to enter into any contracts or assume any obligations for the
other party or make any warranties or representations on behalf of the other
party.
29.
15.15 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original and all of which
together shall constitute one and the same instrument.
In Witness Whereof, the parties hereto have caused this Agreement to be
executed by their duly authorized officers as of the date first above written.
Gene Logic inc. Procter & Xxxxxx
Pharmaceuticals, Inc.
By: /s/ Xxxxxxx X. Xxxxxxx By: /s/ X. X. Xxxxx
------------------------------ ----------------------------------
Name: Xxxxxxx X. Xxxxxxx Name: X.X. Xxxxx
------------------------------ --------------------------------
Title: President and CEO Title: President
--------------------------- -------------------------------
30.
EXHIBIT A
Independent Efforts
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
CONFIDENTIAL TREATMENT REQUESTED
Schedule 3.1
RMC Representatives
Gene Logic Inc.
---------------
Xxxxx X. Xxxxxxxx, Ph.D.
Xxxx X. Xxxxxxx, Ph.D.
Xxxx X. Xxxxxxx
Xxxxxxx & Xxxxxx Pharmaceuticals, Inc.
--------------------------------------
Xxxxx Xxxxxxxxxxx, Ph.D.
Xxxxxxx Xxxxxxxx, Ph.X.
Xxxxx Doersen, Ph.D.
Schedule 9.4
Sample Royalty Calculation
Example
-------
The forecast for Net Sales of Therapeutic Product A in calendar year 2005 is
[***]. The calculation for the royalty is as follows:
[***]
[***]
[***]
[***]
------
TOTAL [***]
Gene Logic invoices P&GP for [***] on April 1, July 1 and October 1 of year
2005.
The actual Net Sales of Therapeutic Product A in calendar year 2005 are
[***]. The calculation for the royalty is as follows:
[***]
[***]
[***]
[***]
------
TOTAL [***]
Gene Logic invoices P&GP for [***].
CONFIDENTIAL TREATMENT REQUESTED
Schedule 9.6
Wire Transfer Payment Instructions
[***]
[***]
[***]
[***]
[***]
[***]
CONFIDENTIAL TREATMENT REQUESTED
